It has been reported that the activation of the enzyme caspase-3 plays a critical role in inducing cancer cell apoptosis, and imatinib, ponatinib, and dasatinib can increase the levels of the caspase-3 by increasing the proteolysis of its inactive zymogen, pro-caspase-3, thereby increasing apoptosis (Quintás-Cardama et al., 2008; Okabe et al., 2014; Wu et al., 2014). The gene discussed is CASP3; the disease is cancer.